Literature DB >> 22664743

Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma.

Xuan Luo1, Songqing Fan, Wenbin Huang, Sulan Zhai, Zhuo Ma, Ping Li, Shi-Yong Sun, Xuerong Wang.   

Abstract

Lymph node metastasis is responsible for the high morbidity of head and neck squamous cell carcinoma (HNSCC). To date, the role of insulin receptor substrate 1 (IRS-1) in tumorigenesis and metastasis of head and neck cancer has not been elucidated. In this study, we found a negative correlation of IRS-1 expression with tumor metastasis both in human tissue samples and in cell lines. Furthermore, we found that knockdown of IRS-1 expression enhanced cell invasive potency and induced EMT in parallel with upregulation of miR-9 expression. We propose that IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664743     DOI: 10.3892/or.2012.1846

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Jiadi Luo; Qiuyuan Wen; Jiao Li; Lina Xu; Shuzhou Chu; Weiyuan Wang; Lei Shi; Guiyuan Xie; Donghai Huang; Songqing Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.

Authors:  Bo Zhou; Hongbin Xu; Meng Xia; Chaoyang Sun; Na Li; Ensong Guo; Lili Guo; Wanying Shan; Hao Lu; Yifan Wu; Yuan Li; Degui Yang; Danhui Weng; Li Meng; Junbo Hu; Ding Ma; Gang Chen; Kezhen Li
Journal:  Front Med       Date:  2017-05-04       Impact factor: 4.592

Review 4.  Frequent chromosomal aberrations and candidate genes in head and neck squamous cell carcinoma.

Authors:  Krzysztof Szyfter; Malgorzata Wierzbicka; Jennifer L Hunt; Alessandra Rinaldo; Juan P Rodrigo; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-30       Impact factor: 2.503

5.  MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma.

Authors:  Zhao Sun; Qin Han; Na Zhou; Shihua Wang; Shan Lu; Chunmei Bai; Robert Chunhua Zhao
Journal:  Mol Oncol       Date:  2013-04-25       Impact factor: 6.603

6.  AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers.

Authors:  Wenbin Huang; Li Yang; Song Liang; Dongxiao Liu; Xi Chen; Zhuo Ma; Sulan Zhai; Ping Li; Xuerong Wang
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

Review 7.  Impact of targeting insulin-like growth factor signaling in head and neck cancers.

Authors:  Kirsten H Limesand; Alejandro Martinez Chibly; Andrew Fribley
Journal:  Growth Horm IGF Res       Date:  2013-06-29       Impact factor: 2.372

8.  MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells.

Authors:  Mengru Cao; Yulian Li; Hailing Lu; Qingwei Meng; Long Wang; Li Cai; Xiaoqun Dong
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-05       Impact factor: 4.553

Review 9.  The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins.

Authors:  Fumihiko Hakuno; Toshiaki Fukushima; Yosuke Yoneyama; Hiroyasu Kamei; Atsufumi Ozoe; Hidehito Yoshihara; Daisuke Yamanaka; Takashi Shibano; Meri Sone-Yonezawa; Bu-Chin Yu; Kazuhiro Chida; Shin-Ichiro Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-26       Impact factor: 5.555

10.  Oncogenic miR-9 is a target of erlotinib in NSCLCs.

Authors:  Xi Chen; Lingjun Zhu; Zhuo Ma; Geng Sun; Xuan Luo; Min Li; Sulan Zhai; Ping Li; Xuerong Wang
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.